Logo image of ZVRA

ZEVRA THERAPEUTICS INC (ZVRA) Stock Fundamental Analysis

USA - NASDAQ:ZVRA - US4884452065 - Common Stock

10.414 USD
-0.24 (-2.22%)
Last: 10/7/2025, 10:32:39 AM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ZVRA. ZVRA was compared to 196 industry peers in the Pharmaceuticals industry. ZVRA has a bad profitability rating. Also its financial health evaluation is rather negative. ZVRA is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

ZVRA had negative earnings in the past year.
ZVRA had a negative operating cash flow in the past year.
ZVRA had negative earnings in each of the past 5 years.
ZVRA had negative operating cash flow in 4 of the past 5 years.
ZVRA Yearly Net Income VS EBIT VS OCF VS FCFZVRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

ZVRA has a Return On Assets of 1.03%. This is amongst the best in the industry. ZVRA outperforms 81.63% of its industry peers.
ZVRA has a Return On Equity of 2.26%. This is amongst the best in the industry. ZVRA outperforms 84.18% of its industry peers.
Industry RankSector Rank
ROA 1.03%
ROE 2.26%
ROIC N/A
ROA(3y)-40.64%
ROA(5y)-56.64%
ROE(3y)-129.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZVRA Yearly ROA, ROE, ROICZVRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

With an excellent Profit Margin value of 4.26%, ZVRA belongs to the best of the industry, outperforming 83.67% of the companies in the same industry.
ZVRA has a better Gross Margin (89.69%) than 92.86% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 4.26%
GM 89.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZVRA Yearly Profit, Operating, Gross MarginsZVRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

ZVRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ZVRA has more shares outstanding
ZVRA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ZVRA is higher compared to a year ago.
ZVRA Yearly Shares OutstandingZVRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ZVRA Yearly Total Debt VS Total AssetsZVRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of 0.60, we must say that ZVRA is in the distress zone and has some risk of bankruptcy.
ZVRA has a Altman-Z score (0.60) which is in line with its industry peers.
ZVRA has a Debt/Equity ratio of 0.52. This is a neutral value indicating ZVRA is somewhat dependend on debt financing.
ZVRA has a worse Debt to Equity ratio (0.52) than 60.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Altman-Z 0.6
ROIC/WACCN/A
WACC8.83%
ZVRA Yearly LT Debt VS Equity VS FCFZVRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 7.85 indicates that ZVRA has no problem at all paying its short term obligations.
ZVRA has a Current ratio of 7.85. This is in the better half of the industry: ZVRA outperforms 77.04% of its industry peers.
ZVRA has a Quick Ratio of 7.81. This indicates that ZVRA is financially healthy and has no problem in meeting its short term obligations.
ZVRA's Quick ratio of 7.81 is fine compared to the rest of the industry. ZVRA outperforms 77.04% of its industry peers.
Industry RankSector Rank
Current Ratio 7.85
Quick Ratio 7.81
ZVRA Yearly Current Assets VS Current LiabilitesZVRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

ZVRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 86.31%, which is quite impressive.
ZVRA shows a strong growth in Revenue. In the last year, the Revenue has grown by 158.51%.
The Revenue has been growing by 12.96% on average over the past years. This is quite good.
EPS 1Y (TTM)86.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%352.08%
Revenue 1Y (TTM)158.51%
Revenue growth 3Y-6.24%
Revenue growth 5Y12.96%
Sales Q2Q%481.73%

3.2 Future

ZVRA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.19% yearly.
ZVRA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 80.69% yearly.
EPS Next Y154.27%
EPS Next 2Y49.92%
EPS Next 3Y41.65%
EPS Next 5Y30.19%
Revenue Next Year392.47%
Revenue Next 2Y175.62%
Revenue Next 3Y130.52%
Revenue Next 5Y80.69%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ZVRA Yearly Revenue VS EstimatesZVRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
ZVRA Yearly EPS VS EstimatesZVRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80 -100

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZVRA. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 18.61, ZVRA is valued on the expensive side.
Based on the Price/Forward Earnings ratio, ZVRA is valued a bit cheaper than 76.53% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ZVRA to the average of the S&P500 Index (23.36), we can say ZVRA is valued slightly cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 18.61
ZVRA Price Earnings VS Forward Price EarningsZVRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZVRA Per share dataZVRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

ZVRA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ZVRA's earnings are expected to grow with 41.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.92%
EPS Next 3Y41.65%

More info and screens

0

5. Dividend

5.1 Amount

ZVRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZEVRA THERAPEUTICS INC

NASDAQ:ZVRA (10/7/2025, 10:32:39 AM)

10.414

-0.24 (-2.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners63.87%
Inst Owner ChangeN/A
Ins Owners0.73%
Ins Owner Change15.16%
Market Cap584.64M
Analysts84.29
Price Target24.48 (135.07%)
Short Float %13.44%
Short Ratio4.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)23.84%
Min EPS beat(2)-20.8%
Max EPS beat(2)68.49%
EPS beat(4)1
Avg EPS beat(4)-20.06%
Min EPS beat(4)-67.34%
Max EPS beat(4)68.49%
EPS beat(8)2
Avg EPS beat(8)-18.58%
EPS beat(12)3
Avg EPS beat(12)-18.77%
EPS beat(16)5
Avg EPS beat(16)-14.97%
Revenue beat(2)2
Avg Revenue beat(2)15.27%
Min Revenue beat(2)12.59%
Max Revenue beat(2)17.95%
Revenue beat(4)3
Avg Revenue beat(4)9.31%
Min Revenue beat(4)-25.59%
Max Revenue beat(4)32.28%
Revenue beat(8)5
Avg Revenue beat(8)2.62%
Revenue beat(12)7
Avg Revenue beat(12)13.34%
Revenue beat(16)9
Avg Revenue beat(16)9.96%
PT rev (1m)1.2%
PT rev (3m)7.01%
EPS NQ rev (1m)39.13%
EPS NQ rev (3m)41.18%
EPS NY rev (1m)77.27%
EPS NY rev (3m)35.9%
Revenue NQ rev (1m)1.07%
Revenue NQ rev (3m)11.15%
Revenue NY rev (1m)1.6%
Revenue NY rev (3m)11.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 18.61
P/S 9.43
P/FCF N/A
P/OCF N/A
P/B 4.99
P/tB 5.54
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)0.56
Fwd EY5.37%
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.82
OCFYN/A
SpS1.1
BVpS2.09
TBVpS1.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.03%
ROE 2.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 4.26%
GM 89.69%
FCFM N/A
ROA(3y)-40.64%
ROA(5y)-56.64%
ROE(3y)-129.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 96.15%
Cap/Sales 10.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.85
Quick Ratio 7.81
Altman-Z 0.6
F-Score5
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)44.3%
Cap/Depr(5y)36.5%
Cap/Sales(3y)9.12%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%352.08%
EPS Next Y154.27%
EPS Next 2Y49.92%
EPS Next 3Y41.65%
EPS Next 5Y30.19%
Revenue 1Y (TTM)158.51%
Revenue growth 3Y-6.24%
Revenue growth 5Y12.96%
Sales Q2Q%481.73%
Revenue Next Year392.47%
Revenue Next 2Y175.62%
Revenue Next 3Y130.52%
Revenue Next 5Y80.69%
EBIT growth 1Y18.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.53%
EBIT Next 3Y44.58%
EBIT Next 5Y33.33%
FCF growth 1Y-119.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.09%
OCF growth 3YN/A
OCF growth 5YN/A